Armelle Logié

2.0k total citations
33 papers, 1.6k citations indexed

About

Armelle Logié is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Armelle Logié has authored 33 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 12 papers in Cancer Research and 8 papers in Surgery. Recurrent topics in Armelle Logié's work include Cancer, Hypoxia, and Metabolism (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Adrenal and Paraganglionic Tumors (6 papers). Armelle Logié is often cited by papers focused on Cancer, Hypoxia, and Metabolism (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Adrenal and Paraganglionic Tumors (6 papers). Armelle Logié collaborates with scholars based in United Kingdom, France and United States. Armelle Logié's co-authors include Paul D. Smith, Barry R. Davies, Christine Gicquel, Yves Le Bouc, Nathalie Boulle, Laurence Périn, Jennifer S. McKay, Richard O. Jenkins, Paul Martin and Mark Cockerill and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Cancer Research and Clinical Cancer Research.

In The Last Decade

Armelle Logié

32 papers receiving 1.5k citations

Peers

Armelle Logié
Lui Ng Hong Kong
Françoise Descôtes France
Peter Shintaku United States
Marie‐Pierre Simon France
Francesco Atzori Italy
Anna L. Stratford Canada
Luis J. Leandro‐García Spain
Stephen Leong United States
Eiwa Ishida Japan
Katharina König Germany
Lui Ng Hong Kong
Armelle Logié
Citations per year, relative to Armelle Logié Armelle Logié (= 1×) peers Lui Ng

Countries citing papers authored by Armelle Logié

Since Specialization
Citations

This map shows the geographic impact of Armelle Logié's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armelle Logié with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armelle Logié more than expected).

Fields of papers citing papers by Armelle Logié

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armelle Logié. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armelle Logié. The network helps show where Armelle Logié may publish in the future.

Co-authorship network of co-authors of Armelle Logié

This figure shows the co-authorship network connecting the top 25 collaborators of Armelle Logié. A scholar is included among the top collaborators of Armelle Logié based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armelle Logié. Armelle Logié is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davies, Barry R., Armelle Logié, Claire Crafter, et al.. (2015). Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Molecular Cancer Therapeutics. 14(11). 2441–2451. 54 indexed citations
2.
Ricketts, Sally‐Ann, Juliana Maynard, Armelle Logié, et al.. (2013). Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055. Molecular Imaging and Biology. 16(3). 421–430. 14 indexed citations
3.
Kendrew, Jane, Rajesh Odedra, Armelle Logié, et al.. (2013). Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemotherapy and Pharmacology. 71(4). 1021–1032. 20 indexed citations
4.
Holt, Sarah V., Armelle Logié, Barry R. Davies, et al.. (2012). Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055). Cancer Research. 72(7). 1804–1813. 70 indexed citations
5.
Holt, Sarah V., Armelle Logié, Rajesh Odedra, et al.. (2012). The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. British Journal of Cancer. 106(5). 858–866. 92 indexed citations
6.
Marshall, Gayle, Zoë Howard, Jonathan R. Dry, et al.. (2011). Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. Biochemical Society Transactions. 39(2). 456–459. 28 indexed citations
7.
Jürgensmeier, Juliane M., Jane Kendrew, Rajesh Odedra, et al.. (2010). Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo. Cancer Research. 70(8_Supplement). 1372–1372. 2 indexed citations
8.
Shannon, Aoife M., Brian A. Telfer, Paul D. Smith, et al.. (2009). The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts. Clinical Cancer Research. 15(21). 6619–6629. 42 indexed citations
9.
Green, Tim P., Jon Curwen, Vivien N. Jacobs, et al.. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology. 3(3). 248–261. 176 indexed citations
10.
Wilkinson, Robert W., Armelle Logié, Nicola J. Curtis, et al.. (2008). Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of in vivo sequencing of drug administration. Cancer Research. 68. 4012–4012. 1 indexed citations
11.
12.
Speake, Georgina, Gayle Marshall, Judith Anderton, et al.. (2006). A pharmacological comparison of gefitinib (IRESSA) and erlotinib. 66. 890–890. 2 indexed citations
13.
Logié, Armelle, et al.. (2005). Pharmacokinetics, tissue distribution and anti-tumor activity of the Src/Abl kinase inhibitor AZD0530 in a rat xenograft model. Cancer Research. 65. 1409–1409. 2 indexed citations
14.
Logié, Armelle, Claire Dunois-Lardé, Christophe Rosty, et al.. (2005). Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Human Molecular Genetics. 14(9). 1153–1160. 122 indexed citations
15.
Boulle, Nathalie, Eric Baudin, Christine Gicquel, et al.. (2001). Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. European Journal of Endocrinology. 144(1). 29–36. 39 indexed citations
16.
Bertherat, Jérôme, et al.. (2000). Alterations of the 11p15 imprinted region and the IGFs system in a case of recurrent non‐islet‐cell tumour hypoglycaemia (NICTH).. Clinical Endocrinology. 53(2). 213–220. 20 indexed citations
17.
Bourcigaux, Nathalie, Véronique Gaston, Armelle Logié, et al.. (2000). High Expression of Cyclin E and G1 CDK and Loss of Function of p57KIP2Are Involved in Proliferation of Malignant Sporadic Adrenocortical Tumors1. The Journal of Clinical Endocrinology & Metabolism. 85(1). 322–330. 51 indexed citations
18.
19.
Logié, Armelle, Nathalie Boulle, Véronique Gaston, et al.. (1999). Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology. 23(1). 23–32. 79 indexed citations
20.
Boulle, Nathalie, Armelle Logié, Christine Gicquel, Laurence Périn, & Yves Le Bouc. (1998). Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tumors1. The Journal of Clinical Endocrinology & Metabolism. 83(5). 1713–1720. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lui Ng Breakdown of academic impact, for papers by Françoise Descôtes Breakdown of academic impact, for papers by Peter Shintaku Breakdown of academic impact, for papers by Marie‐Pierre Simon Breakdown of academic impact, for papers by Francesco Atzori Breakdown of academic impact, for papers by Anna L. Stratford Breakdown of academic impact, for papers by Luis J. Leandro‐García Breakdown of academic impact, for papers by Stephen Leong Breakdown of academic impact, for papers by Eiwa Ishida Breakdown of academic impact, for papers by Katharina König
Rankless by CCL
2026